Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review
Posted inCardiology Clinical Updates Diabetes & Endocrinology news

Glucagon-Like Peptide 1 Receptor Agonists, Mortality, and Cardiovascular Outcomes in Serious Mental Illness: A Comprehensive Review

GLP-1 receptor agonists reduce mortality and cardiovascular events more effectively than SGLT2 inhibitors in serious mental illness (SMI), with early benefits and consistent effects across bipolar disorder, major depression, and schizophrenia. Semaglutide shows particular promise in improving cardiometabolic health.
Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence
Posted inClinical Updates Internal Medicine news Psychiatry

Tailored Weight Loss Interventions for Veterans with Serious Mental Illness: Efficacy and Implementation Insights from Recent RCT Evidence

This review synthesizes evidence from a 2025 randomized clinical trial evaluating a tailored weight loss program, CoachToFit, for veterans with serious mental illness, highlighting its potential to improve weight outcomes via remote support technologies and peer-led interventions.